Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 326–350 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

DNMT3A mutations in acute myeloid leukemia.
· N Engl J Med · 2010 · PMID 21067377 · validated civic_curation pubmed
DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
· Blood Cells Mol Dis · 2014 · PMID 24512939 · validated civic_curation pubmed
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
· Blood · 2005 · PMID 16076867 · validated civic_curation pubmed
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
· Cancer Res · 1996 · PMID 8674046 · validated civic_curation pubmed
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
· Blood · 2008 · PMID 18818391 · validated civic_curation pubmed
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
· Biologics · 2014 · PMID 25349473 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed

Showing 326–350 of 736 publications

← Previous
1
…
13
14
15
…
30
Next →

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

· N Engl J Med · 2016 · PMID 27276561 · validated civic_curation pubmed

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

· N Engl J Med · 2014 · PMID 24869598 · validated civic_curation pubmed

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

· J Clin Oncol · 2005 · PMID 16110030 · validated civic_curation pubmed

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

· J Clin Oncol · 2004 · PMID 15289486 · validated civic_curation pubmed

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

· Nat Genet · 2019 · PMID 30643249 · validated civic_curation pubmed

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

· Blood · 2005 · PMID 16081687 · validated civic_curation pubmed

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

· Nat Genet · 2009 · PMID 19287384 · validated civic_curation pubmed

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

· Oncotarget · 2011 · PMID 22081665 · validated civic_curation pubmed

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

· Blood · 2006 · PMID 16709929 · validated civic_curation pubmed

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

· Blood · 2006 · PMID 16384925 · validated civic_curation pubmed

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

· Blood · 2012 · PMID 22490330 · validated civic_curation pubmed

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

· J Clin Oncol · 2012 · PMID 22291079 · validated civic_curation pubmed

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

· Blood · 2008 · PMID 17957027 · validated civic_curation pubmed

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.

· Leukemia · 2011 · PMID 21537333 · validated civic_curation pubmed

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

· Blood · 2009 · PMID 19221039 · validated civic_curation pubmed

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

· N Engl J Med · 2008 · PMID 18450602 · validated civic_curation pubmed

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

· Blood · 2014 · PMID 24855211 · validated civic_curation pubmed